Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsWPS Health Insurance Prior Auth Policy Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedWPS Health InsurancePolicy N/A

    Drug Prior Authorization List — Pharmacy & Medical Benefit PA Requirements

    Customize your policy alerts

    Sign up for all WPS Health Insurance policy alerts

    Know when WPS Health Insurance releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements and reviewer routing for pharmacy and medical benefit drugs managed by WPS and partner vendors (ESI, CCUM, eviCore); affects providers submitting PA requests and pharmacies seeking coverage exceptions.

    Policy Summary
    PayerWPS Health Insurance
    PolicyDrug Prior Authorization List — Pharmacy & Medical Benefit PA Requirements
    Policy CodePolicy N/A
    Change TypeRevised February 2026
    Effective DateFeb 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to the designated reviewer (ESI, CCUM, eviCore) for each listed drug or to WPS if the PBM cannot complete the review.
    SourceLink
    POLICY UPDATE CHANGES

    Revised: February 2026 — Effective Date: 2/1/2026 (notice that all listed drugs require a PA and PBM routing guidance added).

    All listedRequire prior authorization
    2/1/2026Effective date
    ESI/CCUM/eviCorePrimary reviewer
    1-800-475-1954
    Prior auth phone
    Submit to WPS if PBM unavailablePBM routing

    Coverage Criteria

    General PA approval criteria

    Covered when prior authorization is approved by the designated reviewer and medical necessity is met

    PA requirement: Request must be submitted to the reviewer specified for the drug (ESI, CCUM, eviCore, or WPS).

    All drugs listed require PA; if vendor cannot complete review submit to WPS.

    General PA requirement

    Covered when PA is obtained as required by the plan

    PA requirement: All drugs listed require prior authorization and must be submitted to the specified reviewer (ESI, CCUM, or eviCore). If the listed PBM cannot complete the review, submit to WPS for evaluation.

    Use the reviewer phone numbers listed in each drug entry.

    PA approval required

    Covered when PA is approved by the designated reviewer

    PA submission requirement: Prior authorization must be submitted to the reviewer listed for the drug (ESI, CCUM, eviCore, or WPS).

    This chunk set lists drugs requiring PA and the reviewer; specific clinical criteria are not included in these chunks.

    General PA condition

    Covered when prior authorization is obtained and routed to the designated reviewer

    General PA requirement: Prior authorization must be obtained before coverage for drugs listed in this section; routing to ESI, CCUM, eviCore, or WPS as indicated per drug entry.

    This segment lists reviewer assignments and HCPCS codes but does not include specific medical-necessity clinical criteria.

    General PA requirement

    Covered when prior authorization is obtained and reviewer routing is followed

    PA and reviewer routing: Prior authorization must be obtained for listed drugs and the request must be submitted to the designated reviewer (ESI, CCUM, or eviCore). If those reviewers cannot complete the review, submit to WPS for evaluation.

    No clinical eligibility criteria are provided in this part; this section enumerates drugs and routing.

    General PA coverage condition

    Covered when PA is obtained and processed by the designated reviewer

    PA requirement: Drug is covered when a prior authorization is submitted and approved by the indicated reviewer (ESI, CCUM, or eviCore) or by WPS if the PBM cannot complete review.

    Applies to all listed drugs

    Coverage of services is subject to medical necessity. Services or drugs determined to be experimental, investigational, or unproven under the applicable clinical guidelines will not be covered.

    The provided excerpt does not list any clinical exclusions beyond administrative routing instructions; it states that all drugs on the list require prior authorization and includes a PBM routing note that if a PBM other than ESI is used, submit to that PBM.

    Chunks include drug-specific context (for example, oncology vs non-oncology routing for certain biologics) but do not define explicit clinical exclusions. The listings indicate intended clinical contexts (e.g., Oncology), which inform reviewer routing rather than serving as coverage exclusions.

    The document segments are an administrative list of products that require prior authorization (PA). These chunks provide benefit type, HCPCS/Q-codes where applicable, and the designated reviewer (ESI, CCUM, eviCore or WPS) per drug; they do not specify separate medical exclusions.

    No additional coverage exclusions are specified in these sections beyond the uniform requirement that the listed drugs require prior authorization and must be routed to the reviewer shown for that drug.

    When submitting prior authorization requests, follow the PBM routing guidance provided for each drug. The document instructs that if an alternate PBM is used (i.e., a PBM other than ESI through WPS), providers should submit to that PBM (including pharmacy drugs that would otherwise be reviewed by ESI or eviCore).

    Coverage for drugs listed in this document is contingent on obtaining an approved prior authorization (PA) from the reviewer assigned for that product (ESI, CCUM, eviCore, or WPS when vendors cannot complete review). The chunks do not specify additional clinical exclusions tied to benefit type beyond indicating whether the item is billed under P (Pharmacy) or M (Medical).

    Drugs or services that do not meet the payer’s medical necessity criteria, or that are judged to be experimental, investigational, or unproven, will not be covered. The policy emphasizes that PA determinations are made in the context of medical necessity and applicable clinical guidelines.

    The chunks provided do not state any specific conditions that would be labeled as ‘not medically necessary’ for individual listed drugs. Decisions about medical necessity are made by the designated reviewer using submitted clinical documentation.

    Coding and HCPCS/NDC References

    Sample pharmacy/medical HCPCS codes (segment)HCPCS
    J3490HCPCS Code listed for 5-fluorouracil - topical
    J9190HCPCS Code listed for 5-fluorouracil- injection
    J8499HCPCS Code listed for abacavir/dolutegravir/lamivudi
    Biologic and biosimilar HCPCS codes (segment)HCPCS
    J0135HCPCS Code listed for adalimumab
    Q5131HCPCS Code listed for adalimumab-aacf (biosimilar)
    Sample HCPCS codes from listHCPCS
    J3490adapalene/benzoyl peroxide (listed HCPCS per entry)
    J9354ado-trastuzumab emtansine (KADCYLA)
    J0172aducanumab-avwa (ADUHELM)
    Additional HCPCS/Q codesHCPCS
    J7352afamelanotide acetate (SCENESSE)
    Q2057afamitresgene autoleucel (TECELRA)
    J8999afatinib - oral (GILOTRIF)
    J0177aflibercept (HD) (EYLEA) - HCPCS listed
    C9161aflibercept (HD) alternate code
    Biosimilars and enzyme codesHCPCS
    Q5149aflibercept-abzv (ENZEEVU)
    Q5147aflibercept-ayyh (PAVBLU)
    Q5155aflibercept-jbvf (AVTOZMA)
    Q5150aflibercept-mrbb (AHZANTIVE)
    Q5153aflibercept-yszy (OPUVIZ)
    J0180alglucosidase alfa (MYOZYME)
    J0220alglucosidase alfa (MYOZYME alternate)
    Miscellaneous HCPCS codesHCPCS
    J3590alirocumab (PRALUENT) / anakinra (KINERET) (listed as J3590/J3490 variants)
    J8499Various oral/other drugs listed with J8499 (e.g., albiglutide, alendronate, alogliptin)
    J9015aldesleukin (PROLEUKIN)
    Oncology and neurology agentsHCPCS
    J9061amivantamab-vmjw (RYBREVANT)
    G9033amantadine hcl (GOCOVRI) - ancillary code listed
    Hemophilia factor HCPCS codesHCPCS
    J7210antihem.fviii, sin-chn, b-dm tru (AFSTYLA)
    J7207antihemo.fviii, full length peg (ADYNOVATE)
    J7205antihemoph.fviii rec, fc fusion (ELOCTATE)
    J7185antihemoph.fviii, b-domain del / antihemophilic factor (recombinant) (XYNTHA SOLOFUSE / XYNTHA)
    J7192antihemophilic factor (recombinant) (HELIXATE FS / NOVOEIGHT variants)
    J7190antihemophilic factor (human) (HEMOFIL M / KOATE)
    Listed HCPCS/Codes in excerptHCPCS
    J7192antihemophil.fviii, full length / antihemophilic factor (recombinant) (various entries)
    J7190antihemophilic factor (human)
    J7182antihemophilic factor (recombinant) NOVOEIGHT
    J7185antihemophilic factor (recombinant) XYNTHA
    J7211antihemophilic factor (recombinant) KOVALTRY
    J7191antihemophilic factor, human / MONOCLATE-P
    J7183antihemophilic factor/vwf WILATE
    J7186antihemophilic factor/vwf ALPHANATE
    J7187antihemophilic factor/vwf HUMATE-P
    J7188antihemophilic fviii, rec porc OBIZUR
    1–10 of 30
    1/3
    Sample HCPCS Codes (multiple drugs)HCPCS
    J8499Used for multiple listed pharmacy products (example: azilsartan)
    J3490Used for multiple listed products (example: aztreonam lysine inhalation)
    Covered HCPCS Codes (examples)HCPCSCovered
    J9030BCG
    J0485Belatacept
    J0490Belimumab
    J9032Belinostat
    J3401Beremagene geperpavec-svdt
    J9040Bleomycin
    J9039Blinatumomab
    Bendamustine/Bortezomib HCPCS groupHCPCSCovered
    J9041Bortezomib
    J9044Bortezomib related code
    J9046Bortezomib (Dr. Reddy's)
    J9048Bortezomib (Fresenius Kabi)
    J9049Bortezomib (Hospira)
    J9051Bortezomib (Maia)
    J9054Bortezomib code
    J9056Bendamustine (Vivimusta)
    Bevacizumab and biosimilarsHCPCSCovered
    C9257Bevacizumab (specific code)
    J9035Bevacizumab
    Q5129Bevacizumab-adcd (VEGZELMA)
    Q5107Bevacizumab-awwb (MVASI)
    Q5118Bevacizumab-bvzr (ZIRABEV)
    Q5160Bevacizumab-nwgd (JOBEVNE)
    CAR-T therapy codesHCPCSCovered
    C9073Brexucabtagene autoleucel
    Q2053Brexucabtagene autoleucel
    Miscellaneous HCPCS codes from listHCPCS
    J7351Bimatoprost
    J8999Non-specific oral drug codes (used for several oral products listed)
    J1632Brexanolone
    J3393Betibeglogene autotemcel
    J0179Brolucizumab-dbll
    J0584Burosumab-twza
    Listed HCPCS/CodesHCPCS
    J8999listed for multiple oral drugs (placeholder HCPCS for oral pharmacy benefit)
    J8499listed for multiple drugs (miscellaneous HCPCS)
    J3590brodalumab HCPCS
    J0179brolucizumab-dbll HCPCS
    J0584burosumab-twza HCPCS
    J0598c1 esterase inhibitor HCPCS
    J0597c1 esterase inhibitor HCPCS
    J0599c1 esterase inhibitor HCPCS
    J0596c1 esterase inhibitor, recomb HCPCS
    J9043cabazitaxel HCPCS
    1–10 of 40
    1/4
    Drugs with HCPCS (sample group)HCPCS
    J9060cisplatin
    J8499cladribine (one alt HCPCS listed)
    J9065cladribine
    HCPCS codes for drugs listed in this segmentHCPCSCovered
    J3490multiple topical/oral agents (example entries)
    J9027clofarabine
    J7195coagulation factor ix (recombinant)
    J7189coagulation factor viia, recomb
    J7213coagulation factor ix (recombinant) alternate
    J7212coagulation viia, recomb-jncw (SEVENFACT)
    J7175coagulation factor x (COAGADEX)
    J0775collagenase clostridium hist.
    J7173concizumab
    J0800corticotropin (H.P. ACTHAR GEL)
    1–10 of 37
    1/4
    Sample drug HCPCS codes (partial list from chunk 108)HCPCS
    J8999dasatinib - oral (listed with J8999 in this document)
    J9011datopotamab deruxtecan-dlnk
    C9174datopotamab deruxtecan-dlnk
    J9150daunorubicin
    HCPCS codes (continued from chunks 109-127)HCPCS
    J9153daunorubicin/cytarabine liposome (VYXEOS LIPOSOME)
    J0589daxibotulinumtoxinA-lanm
    J0894decitabine
    J0893decitabine (sun pharma)
    J8499multiple oral or pharmacy benefit drugs listed (placeholder miscellaneous code)
    J0897denosumab
    C9399denosumab-bbdz
    J3490denosumab-bbdz / miscellaneous J-code uses
    J9999denosumab-bbdz / miscellaneous
    Q5157denosumab-bmwo
    1–10 of 33
    1/4
    Selected HCPCS codes (eculizumab group)HCPCS
    J1299HCPCS code listed for eculizumab
    J1300HCPCS code listed for eculizumab
    Q5151HCPCS code listed for eculizumab-abzv (biosimilar)
    Q5139HCPCS code listed for eculizumab-aeeb (biosimilar)
    Q5152HCPCS code listed for eculizumab-aeeb (biosimilar)
    HCPCS / unclassified drug codes (mixed list)HCPCS
    J1301HCPCS code listed for edaravone
    C9493Alternate HCPCS code listed for edaravone
    J9361HCPCS code listed for efbemalenograstim alfa-vuxw
    J9334HCPCS code listed for efgartigimod alfa and hyaluronidase-qvfc
    J9332HCPCS code listed for efgartigimod alfa-fcab
    J1449HCPCS code listed for eflapegrastim-xnst
    J8999Generic J-code used for various oral/other oncology drugs
    J3490Unclassified drug HCPCS code
    J3590Unclassified drug HCPCS code
    C9399C-code used for certain drugs (listed for eladocagene and eplontersen)
    1–10 of 29
    1/3
    Example HCPCS codes (partial from chunk)HCPCS
    J8999estramustine - oral (listed HCPCS)
    J8499eszopiclone (listed HCPCS)
    J1438etanercept (listed HCPCS)
    J0606etelcalcetide hydrochloride (listed HCPCS)
    HCPCS codes (partial from chunk)HCPCS
    J1428eteplirsen (listed HCPCS)
    J9181etoposide - inj (listed HCPCS)
    J8560etoposide - oral (listed HCPCS)
    HCPCS codes (additional examples)HCPCS
    J1411etranacogene dezaparvovec (HEMGENIX) HCPCS
    J1305evinacumab-dgnb (EVKEEZA) HCPCS
    J3590evolocumab (REPATHA) HCPCS
    J7194factor ix cplx(pcc)no4 HCPCS
    J7203factor ix human rec, pegylated HCPCS
    J7195factor ix human recombinant (BENEFIX) HCPCS
    J7200factor ix human recombinant (RIXUBIS) HCPCS
    J7201factor ix rec, fc fusion protn (ALPROLIX) HCPCS
    J7199factor ix recom, albumin fusion HCPCS
    HCPCS/Q-codes (partial)HCPCS
    J7214factor VIII, recombinant human with VWF fusion HCPCS
    J7181factor xiii a-subunit, recomb HCPCS
    J7180factor xiii HCPCS
    J9358fam-trastuzumab deruxtecan-nxki (ENHERTU) HCPCS
    J2777faricimab-svoa (VABYSMO) HCPCS
    Q5110filgrastim-aafi (NIVESTYM) Q-code
    Q5101filgrastim-sndz (ZARXIO) Q-code
    HCPCS codes (additional)HCPCS
    J1440fecal microbiota, live (VOWST) HCPCS
    J8499febuxostat / fenfluramine / many oral drugs (generic J8499 placeholder)
    J3490exenatide / fentanyl (generic J3490 placeholder)
    J7177fibrinogen (FIBRYGA) HCPCS
    J7178fibrinogen concentrate (RIASTAP) HCPCS
    HCPCS codes (more examples)HCPCS
    J9185fludarabine phosphate HCPCS
    J9200floxuridine HCPCS
    J7311fluocinolone acetonide (RETISERT) HCPCS
    J7313fluocinolone acetonide (ILUVIEN) HCPCS
    J7314fluocinolone acetonide (YUTIQ) HCPCS
    J8499fluoxetine HCPCS (placeholder)
    HCPCS/S-codes (additional)HCPCS
    J8999flutamide - oral HCPCS (placeholder)
    J3490fluticasone nasal HCPCS (placeholder)
    S0126follistim / follitropin alfa HCPCS/S-code
    J1434fosaprepitant
    J1453fosaprepitant (EMEND)
    J1456fosaprepitant (TEVA)
    J1809fosdenopterin (NULIBRY)
    J7356foslevodopa and foscarbidopa (VYALEV)
    Listed HCPCS codesHCPCS
    S0126follitropin alfa
    Listed HCPCS codesHCPCS
    J1434fosaprepitant
    J1453fosaprepitant (EMEND)
    Listed HCPCS codesHCPCS
    J1456fosaprepitant (TEVA)
    J1809fosdenopterin (NULIBRY)
    J7356foslevodopa and foscarbidopa (VYALEV)
    Listed HCPCS codesHCPCS
    J1454fosnetupitant/palonosetron (AKYNZEO)
    J8499fostamatinib disodium (TAVALISSE)
    Listed HCPCS codesHCPCS
    J3031fremanezumab-vfrm (AJOVY)
    J8499frovatriptan succinate (FROVA)
    J9395fruquintinib - oral (FRUZAQLA)
    Listed HCPCS codesHCPCS
    J9395fulvestrant (FASLODEX)
    J9394fulvestrant (FRESENIUS KABI)
    J9393fulvestrant (TEVA)
    Listed HCPCS codesHCPCS
    J8999futibatinib - oral (LYTGOBI)
    J7192fviii rec, b-dom delet peg-aucl (JIVI)
    J7208fviii rec, b-dom delet peg-aucl
    J7204fviii rec, b-dom trunc peg-exei (ESPEROCT)
    Listed HCPCS codesHCPCS
    J8499gabapentin (HORIZANT)
    J8499galcanezumab (EMGALITY)
    J1458galsulfase (NAGLAZYME)
    J8499ganaxolone (ZTALMY)
    Listed HCPCS codesHCPCS
    S0132ganirelix acetate (ANTAGON)
    Listed HCPCS/other codesHCPCS
    C9399garadacimab subcutaneous injection
    J8565gefitinib - oral (IRESSA)
    J9201gemcitabine (GEMZAR)
    J9184gemcitabine hcl
    J9196gemcitabine hcl
    Listed HCPCS codesHCPCS
    J9198gemcitabine hcl in nacl (INFUGEM)
    J9203gemtuzumab ozogamicin (MYLOTARG)
    J8999gilteritinib - oral (XOSPATA)
    J0223givosiran sodium (GIVLAARI)
    Listed HCPCS/CodesHCPCS
    C9056givosiran sodium
    J8999glasdegib - oral (DAURISMO)
    J1595glatiramer acetate
    J3490glatiramer acetate (alternative billing)

    Provider Actions and Submission Instructions

    Prior Authorization

    Prior authorization required for all listed drugs

    All drugs listed in this policy require prior authorization (PA). Submit the PA to the reviewer specified for the drug (ESI, CCUM, eviCore, or WPS). If the listed reviewer cannot complete the review, submit the request to WPS for evaluation.

    • Applies to every drug on the list — PA is required before coverage is approved.
    • Use the vendor assignment shown next to each drug entry (ESI, CCUM, eviCore) or WPS if the vendor cannot complete the review.
    Prior Authorization

    Submit PA to alternate PBM/vendor when applicable

    When the group uses an alternate PBM or vendor (not ESI/CCUM/eviCore), submit prior authorization requests to the applicable PBM/vendor and follow that vendor's precertification process.

    • Includes pharmacy drugs reviewed by ESI or eviCore — submit to the other PBM when applicable.
    • If the external vendor cannot complete the review, escalate submission to WPS for evaluation.

    Initial Therapy Criteria

    Initial therapy PA

    Initial: Prior authorization required prior to initial dispensing/administration for all listed drugs.

    Refer to vendor specified for individual drug entry.

    Initial therapy PA

    Administrative PA required for initiation

    PA for listed drug: All drugs listed require prior authorization before coverage as indicated by the document; submit to the reviewer shown for that drug.

    Specific clinical initiation criteria not included in these chunks.

    Step Therapy

    Step therapy accessNotes
    Providers may obtain specific step therapy criteria by calling the prior authorization specialist at 1-800-475-1954Also consult eviCore clinical guidelines at https://www.evicore.com/provider/clinical-guidelines (select Medical Oncology or Radiation Oncology and search 'WPS Health Insurance')
    Step therapyNotes
    No specific step therapy steps specified in this excerptGeneral instruction: follow PBM reviewer routing (ESI, CCUM, eviCore) and submit to WPS if the PBM cannot complete the review
    Step therapyNotes
    Reviewer routing differs by indication and may function operationally as step determinationExample: CCUM for non-oncology (option 2) and eviCore for oncology (option 3); routing noted per drug entry
    Step therapyNotes
    Step therapy rules not specified in these chunksPA routing and reviewer assignment are provided per drug; follow reviewer indicated (ESI, CCUM, eviCore) and submit to WPS if needed
    Step therapyNotes
    Step therapy not specified in this segmentDocument provides PA requirement and reviewer routing (e.g., CCUM or eviCore) but no clinical step algorithm
    Step therapyNotes
    No step therapy rules specifiedOnly PA requirement and reviewer routing are listed; follow vendor-specific criteria where applicable
    Step therapy (PBM routing)Notes
    If a PBM other than ESI through WPS is used, submit the prior authorization to that PBMIncludes pharmacy drugs reviewed by ESI or eviCore; if external PBM cannot complete review submit to WPS for evaluation

    Site of Care and Benefit Type Notes

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Biosimilar and Specific Drug Notes

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background

    Prior authorization is used to ensure appropriate use of selected drugs and to confirm medical necessity before coverage. The policy notes that services deemed experimental, investigational, or unproven are not covered and that reviewers use medical records, FDA labeling, and evidence-based literature when making determinations.

    Definitions and Key Fields

    Prior authorization (definition)
    DefinitionPrior authorization: a process used to determine if a drug meets medical necessity requirements before coverage is approved.
    PurposeEnsures appropriate use and confirms medical necessity prior to coverage.
    Coverage LimitationServices deemed experimental, investigational, or unproven will not be covered under medical necessity rules.
    Benefit Type
    Benefit Type indicatorP = Pharmacy or M = Medical as shown per drug entry.
    UsageBenefit Type determines billing pathway and reviewer routing (medical-administered products have HCPCS codes).
    Policy Summary
    PayerWPS Health Insurance
    PolicyDrug Prior Authorization List — Pharmacy & Medical Benefit PA Requirements
    Policy CodePolicy N/A
    Change TypeRevised February 2026
    Effective DateFeb 1, 2026
    Last ReviewFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to the designated reviewer (ESI, CCUM, eviCore) for each listed drug or to WPS if the PBM cannot complete the review.
    SourceLink
    On This Page
    Coverage CriteriaCoding and HCPCS/NDC ReferencesProvider Actions and Submission InstructionsInitial Therapy CriteriaStep TherapySite of Care and Benefit Type NotesBiosimilar and Specific Drug NotesBackgroundDefinitions and Key Fields
    Listed HCPCS codesHCPCS
    J8499glecaprevir/pibrentasvir (MAVYRET)
    J9286glofitamab-gxbm (COLUMVI)
    J1610glucagon (GVOKE)
    Listed HCPCS/CodesHCPCS
    C9293glucarpidase (VORAXAZE)
    J8499glutamine (ENDARI)
    J8499glycerol phenylbutyrate (RAVICTI)
    J3590golimumab (SIMPONI)
    Listed HCPCS codesHCPCS
    J1602golimumab (SIMPONI ARIA)
    J1429golodirsen (VYONDYS 53)
    J1620gonadorelin (FACTREL / LUTREPULSE)
    Listed HCPCS codesHCPCS
    J0725gonadotropin (CHORIONIC GONADOTROPIN)
    J3355gonadotropin (UROFOLLITROPIN)
    J9202goserelin acetate implant (ZOLADEX)
    Listed HCPCS codesHCPCS
    J8499gr pol-orc/sw ver/rye/kent/tim (ORALAIR)
    J1627granisetron - subcutaneous (SUSTOL)
    J3490granisetron - transdermal (SANCUSO)
    Listed HCPCS codesHCPCS
    J8499grass pollen-timothy, standard (GRASTEK)
    Listed HCPCS codesHCPCS
    J1628guselkumab (TREMFYA IV/SQ)
    J1640hemin (PANHEMATIN)
    J9226histrelin acetate (SUPPRELIN LA, VANTAS)
    Listed HCPCS codesHCPCS
    J1746ibalizumab-uiy (TROGARZO)
    J8499ibandronate sodium
    J1740ibandronate sodium (BONIVA)
    Listed HCPCS codesHCPCS
    J8999ibrutinib - oral (IMBRUVICA)
    J1744icatibant acetate (FIRAZYR / SAJAZIR / ICATIBANT)
    Drugs listed (sample from chunk 180)HCPCS
    J1746ibalizumab-uiy (TROGARZO)
    J8499ibandronate sodium (generic listing)
    J1740ibandronate sodium (BONIVA)
    Drugs listed (sample from chunk 181)HCPCS
    J8999ibrutinib - oral (IMBRUVICA) / other oral oncology agents
    J1744icatibant acetate (FIRAZYR)
    Drugs and HCPCS codes (expanded group)HCPCS
    J9211idarubicin hcl - inj (IDAMYCIN)
    C9081idecabtagene vicleucel (ABECMA)
    Q2055idecabtagene vicleucel (ABECMA)
    J1743idursulfase (ELAPRASE)
    J9208ifosfamide (IFEX, MITOXANA)
    J1572imm glob g (igg)/sorb/iga 0-50 (FLEBOGAMMA)
    J1562imm glob sc/scig/igsc (VIVAGLOBIN)
    J1557immun glob g(igg)/gly/iga 0-50 (GAMMAPLEX)
    J1555immun glob g(igg)/gly/iga ov50 (CUVITRU)
    J1556immun glob g(igg)/gly/iga ov50 (BIVIGAM)
    1–10 of 37
    1/4
    Listed HCPCS Codes (examples from this chunk)HCPCS
    J9216interferon gamma-1b, recomb.
    Listed HCPCS CodesHCPCS
    J8499iptacopan (FABHALTA) or other oral drugs billed under J8499
    J9206irinotecan (CAMPTOSAR)
    J9205irinotecan liposome (ONIVYDE)
    Listed HCPCS CodesHCPCS
    J9227isatuximab-irfc (SARCLISA)
    J0738lenacapavir (YEZTUGO) - HCPCS codes listed
    J0752lenacapavir (YEZTUGO) - HCPCS codes listed
    Listed HCPCS CodesHCPCS
    J9153liposome-encapsulated combination of daunorubicin and cytarabine (VYXEOS)
    Leuprolide HCPCS CodesHCPCS
    J1950leuprolide acetate (various)
    J9217leuprolide acetate
    J9218leuprolide acetate
    J9219leuprolide acetate
    Cell therapy HCPCS/CodesHCPCS
    C9076lisocabtagene maraleucel (BREYANZI)
    Listed HCPCS/CodesHCPCS
    C9307linvoseltamab-gcpt (LYNOZYFIC)
    Listed HCPCS/CodesHCPCS
    J9153liposome-encapsulated combination of daunorubicin and cytarabine (VYXEOS)
    J3490liraglutide (VICTOZA) / lixisenatide (ADLYXIN) and other J3490 entries
    J8499lisdexamfetamine (VYVANSE) and other J8499 entries
    C9076lisocabtagene maraleucel (BREYANZI)
    Additional HCPCS/CodesHCPCS
    Q2054alternate code listed for lisocabtagene maraleucel
    J9359loncastuximab tesirine-lpyl (ZYNLONTA)
    J8999lorlatinib - oral (LORBRENA) / midostaurin - oral (RYDAPT) and other J8999 entries
    J3394lovotibeglogene autotemcel (LYFGENIA)
    J0224lumasiran sodium (OXLUMO)
    C9074lumasiran sodium alternate code
    J9353margetuximab-cmkb (MARGENZA)
    J9223lurbinectedin (ZEPZELCA)
    J0896luspatercept-aamt (REBLOZYL)
    J7172marstacimab-hncq (HYMPAVZI)
    1–10 of 18
    1/2
    Listed HCPCS codesHCPCS
    J1202miglustat
    Listed HCPCS codesHCPCS
    J8499milnacipran; minocycline; minocycline hcl microspheres; mirabegron; mitapivat sulfate; monomethyl fumarate; niraparib - oral; many others in this section
    J3490mipomersen; naloxone auto injector; octreotide acetate; others listed
    Listed HCPCS codesHCPCS
    J2267mirikizumab-mrkz
    J9063mirvetuximab soravtansine-gynx
    Q5134natalizumab (biosimilar)
    Listed HCPCS codesHCPCS
    J2350ocrelizumab
    J2351ocrelizumab and hyaluronidase-ocsq
    Listed HCPCS codesHCPCS
    J8999various oral oncology agents (e.g., mirdametinib - oral; neratinib; nilotinib; niraparib; others)
    J9299nivolumab
    J9289nivolumab and hyaluronidase-nvhy
    Sample listed HCPCS (partial list)HCPCS
    J2350ocrelizumab HCPCS code as listed
    J2351ocrelizumab and hyaluronidase-ocsq HCPCS code as listed
    J3490octreotide acetate HCPCS code as listed
    Additional HCPCS/J-codesHCPCS
    J8999Oral drugs (examples: olaparib, olutasidenib, osimertinib, palbociclib, etc.) coded to J8999 as listed
    J0218olipudase alfa-rpcp HCPCS code
    J9267paclitaxel HCPCS code
    J9258paclitaxel (albumin-bound) HCPCS code
    J9264paclitaxel (albumin-bound) HCPCS code (alternate)
    High-cost biologic/gene therapy codesHCPCS
    J0222patisiran sodium, lipid complex HCPCS code
    C9151pegcetacoplan HCPCS code
    J9266pegaspargase HCPCS code
    N/A (placeholder from source)
    N/AN/A
    NoteThis placeholder appears in the source with no actionable threshold or code mapping.
    ContextRetained in document as an administrative marker within the coding section.
    Prior authorization requirement
    RequirementAll drugs listed require prior authorization (PA).
    RoutingSubmit PA to the reviewer indicated per drug (ESI, CCUM, eviCore) or to WPS if the vendor cannot complete the review.
    ScopeApplies to both Pharmacy and Medical benefit drugs listed in this document.
    Effective Date
    Effective Date2/1/2026
    Revision NoteRevised: February 2026 (appears in header near effective date).
    ApplicabilityEffective date shown across multiple list segments and applies to all listed PA requirements.
    Effective Date (alternate)
    Effective Date (alt)2/1/2026
    PBM noteIf using a PBM other than ESI through WPS, submit to that PBM (instruction appears with effective date).
    RevisionRevised: February 2026 (noted near effective date).
    Effective Date (misc)
    Effective Date (misc)Effective Date: 2/1/2026 indicated in multiple chunks.
    Operational ImpactReviewer routing and PA requirement statements reference the effective date in section headers.
    InstructionFollow reviewer routing (ESI/CCUM/eviCore) as of the effective date; escalate to WPS if reviewer cannot complete review.
    Prior Authorization

    Obtain PA and submit to designated reviewer

    Prior authorization must be obtained for every drug on the list and routed to the reviewer indicated for that specific drug (ESI, CCUM, or eviCore). If the designated PBM cannot complete the review, submit to WPS.

    • Use the reviewer contact shown in the drug entry (vendor phone numbers provided).
    • Coverage is contingent on PA approval by the designated reviewer.
    Prior Authorization

    Follow reviewer routing and use provided contact numbers

    Prior authorization is required for each listed drug; the policy shows which reviewer handles each drug and provides reviewer phone numbers for submission. If the vendor cannot complete the review, submit to WPS.

    • Reviewer assignments (ESI, CCUM, eviCore or WPS) are provided per drug entry with contact lines.
    • Follow the reviewer routing noted in the drug listing when submitting PA requests.
    Documentation Required

    Include HCPCS/CPT codes and route PA to named reviewer

    A prior authorization is required for each product listed; the document supplies HCPCS/CPT or miscellaneous codes and identifies the designated reviewer to which the PA must be routed.

    • Include the HCPCS/CPT or J-code listed for the product when preparing the PA submission.
    • Route the request to the reviewer named in the drug entry (ESI, CCUM, eviCore, or WPS).
    Prior Authorization

    Submit PA to the designated reviewer (or WPS if vendor unavailable)

    Submit prior authorization requests to the reviewer indicated for the drug. If the indicated reviewer cannot complete the review, submit the PA to WPS for evaluation using the WPS provider contact.

    • Use the vendor phone number listed in the drug entry (e.g., 1-800-475-1954 for ESI/CCUM/eviCore).
    • If vendor review cannot be completed, submit to WPS at 1-800-333-5003.
    Prior Authorization

    Submit PA to the reviewer listed for that drug

    Prior authorization must be submitted to the reviewer identified for that drug entry (ESI, CCUM, eviCore or WPS); follow the reviewer assignment shown in the policy.

    • Reviewer assignment and the HCPCS/J-code are shown for each drug — submit both as part of the request.
    • If the reviewer cannot complete the review, escalate the request to WPS.
    Documentation Required

    Use reviewer assignment and HCPCS codes from drug entry

    Each listed drug requires prior authorization; the policy lists reviewer assignments and HCPCS/J-codes per product — submit the PA to the reviewer shown for that code.

    • Include benefit type (P or M) and the HCPCS/J-code in the PA submission per the drug entry.
    • Route to ESI, CCUM, or eviCore as indicated; if those reviewers cannot complete the review, submit to WPS.
    Prior Authorization

    Route PA by benefit type to the reviewer indicated

    The policy lists benefit type and the reviewer routing for each drug. Submit PA requests to the reviewer shown (ESI, CCUM, or eviCore) according to the drug’s benefit type and routing instruction.

    • Benefit Type indicates Pharmacy (P) or Medical (M) — use this when determining submission process.
    • If external reviewer cannot complete review, submit to WPS for evaluation.
    Prior Authorization

    If PBM reviewer cannot complete review, submit to WPS

    If the PBM for the group is unavailable or unable to complete the review, route the prior authorization request to the appropriate vendor (ESI, CCUM, eviCore) or submit directly to WPS for evaluation.

    • Primary vendor phone line for ESI/CCUM/eviCore: 1-800-475-1954.
    • WPS provider contact for escalation: 1-800-333-5003.
    Prior Authorization

    Contact designated reviewer or submit per routing instructions

    All drugs on this list require prior authorization; contact the designated reviewer via the vendor phone number listed in the drug entry or submit per the routing instructions in the policy.

    • Use vendor contact 1-800-475-1954 for ESI/CCUM/eviCore.
    • If vendor cannot complete the review, submit the PA to WPS at 1-800-333-5003.
    Documentation Required

    Submit PA for listed HCPCS/CPT codes to assigned reviewer

    Prior authorization is required for the HCPCS/CPT codes listed with each drug; submit PA to ESI, CCUM, or eviCore as indicated, and use WPS if the PBM cannot complete the review.

    • Include the HCPCS/J-code shown in the drug entry when requesting PA.
    • Route to the reviewer indicated (CCUM, ESI, eviCore); escalate to WPS if needed.
    Prior Authorization

    Submit PA to assigned reviewer; escalate to WPS if needed

    Reviewer assignment is indicated for each drug; submit prior authorization requests to the assigned reviewer (ESI, CCUM, eviCore) and use WPS as the escalation path if the reviewer cannot complete the review.

    • Reviewer phone numbers for vendors and WPS are provided in the document.
    • Follow the per‑drug reviewer assignment when submitting PAs.
    Prior Authorization

    Submit to designated reviewer; WPS accepts submissions if PBM cannot complete review

    Submit the prior authorization to the reviewer shown for that drug entry; if the PBM reviewer is unable to complete the review, WPS will accept the submission for evaluation.

    • Use the reviewer assignment (e.g., CCUM option 2 for certain products) shown next to the drug.
    • When vendor review cannot be completed, submit to WPS at 1-800-333-5003.
    Documentation Required

    Submit PA to indicated reviewer; include supporting clinical information

    Prior authorization must be submitted to the reviewer indicated for the drug (ESI, CCUM, or eviCore). If those reviewers cannot complete the review, submit the PA to WPS for evaluation.

    • Provide the drug name and supporting clinical information with the PA submission.
    • Use the vendor phone numbers provided in the policy when contacting external reviewers.
    Documentation Required

    Submit PA with clinical support to designated reviewer or WPS

    Submit prior authorization requests to the reviewer identified for the drug; if the PBM cannot complete the review, submit to WPS for evaluation using the WPS contact information provided.

    • Include the HCPCS/J-code and clinical justification (medical records, prior treatments, FDA labeling) when submitting PA.
    • If using a PBM other than ESI through WPS, submit to that PBM per the group’s arrangement.
    Note

    Call 1-800-475-1954 for step therapy or PA criteria

    Providers may obtain detailed step therapy or prior authorization criteria by calling the prior authorization specialist at 1-800-475-1954 for drugs reviewed by Express Scripts or Care Continuum.

    • Call 1-800-475-1954 to speak with a prior authorization specialist for step therapy or PA requirements.
    • For eviCore step-therapy/guideline details, consult eviCore’s provider clinical guidelines online.
    Note

    No step therapy rules specified in this excerpt

    The policy does not provide step therapy algorithms or specific step requirements in the listed excerpts.

    • No explicit step therapy rules are specified in this document segment; follow PBM/vendor guidance or contact the prior authorization specialist for details.
    Note

    Note — limited excerpt

    (No additional requirements specified in this excerpt.)

    Prior Authorization

    Follow oncology vs non‑oncology reviewer routing

    Some oncology biologics show different reviewer routing for oncology versus non-oncology use (e.g., CCUM for non-oncology, eviCore for oncology); follow the routing in the drug entry when submitting PAs.

    • Check the drug’s comments for routing differences by indication (oncology vs non‑oncology).
    • Submit to eviCore for oncology indications when indicated; submit to CCUM/ESI for non‑oncology as shown.
    Note

    Step therapy not specified — follow vendor guidance

    Step therapy is not defined in these chunks; the policy reiterates PA routing instructions without specifying step-therapy steps.

    • If step therapy is required, contact the prior authorization specialist or the assigned PBM for details.
    • Do not assume step therapy rules from this excerpt; use vendor guidance.
    Note

    No step therapy rules in this segment

    No step therapy rules or additional PA routing beyond reviewer assignments are provided in this segment.

    Note

    No step therapy rules provided

    No step therapy rules are provided in these chunks; the policy focuses on PA requirement and reviewer routing.

    Note

    Step therapy not specified here

    No step therapy rules are specified in these chunks; submit PAs per PBM routing instructions.

    Note

    Step therapy not specified in provided chunks

    No step therapy rules are specified in the provided segments of the policy.

    Note

    Placeholder

    (No content — placeholder.)

    Prior Authorization

    Follow per‑drug reviewer/program assignment

    Reviewer routing and program assignment differ for some products — e.g., certain drugs route to eviCore for oncology reviews and to CCUM or ESI for non‑oncology; follow the routing shown per drug entry.

    • Confirm indication in the patient's record to determine correct reviewer routing.
    • If the reviewer indicated cannot complete the review, submit to WPS.
    Prior Authorization

    Submit PA to other PBM when group does not use ESI through WPS

    If the group uses a PBM other than ESI through WPS, submit the PA to that PBM for review (this includes pharmacy drugs that would otherwise be reviewed by ESI or eviCore under WPS arrangements).

    • Follow the alternate PBM’s precertification process and contact information.
    • If the alternate PBM cannot complete the review, escalate to WPS for evaluation.
    Note

    Placeholder

    (Miscellaneous placeholder — no provider action in excerpt.)

    Note

    Placeholder

    (No content in this placeholder.)

    Prior Authorization

    Submit PA to other PBM when applicable

    If the sponsor uses a different PBM, submit PA requests to that PBM rather than the ESI/CCUM/eviCore contacts listed in this policy.

    Documentation Required

    Provide medical records and supporting clinical information with PA

    Decision-makers use the patient’s medical records, prior treatments, FDA labeling, and peer‑reviewed literature as supporting documentation during PA review — include these when submitting a request.

    • Provide relevant medical records and prior treatment history.
    • Include FDA labeling and any supporting literature or evidence-based guidelines where applicable.
    Prior Authorization

    Submit PA to the listed reviewer or escalate to WPS

    Submit PA requests to the reviewer listed in the drug entry using the vendor phone numbers provided; if the vendor cannot complete the review, submit the PA to WPS for evaluation.

    • Use vendor contact 1-800-475-1954 for ESI/CCUM/eviCore.
    • If vendor review cannot be completed, submit to WPS at 1-800-333-5003.
    Prior Authorization

    Escalate to WPS when vendor cannot complete review

    When PBMs (ESI, CCUM, eviCore) cannot complete the review, submit the PA to WPS; if the group uses another PBM, submit to that PBM per group arrangement.

    • If using another PBM, follow its submission process (e.g., iExchange or fax form per WPS instructions).
    • WPS will evaluate requests when external reviewers cannot complete reviews.
    Documentation Required

    Submit PA to listed reviewer or to WPS if PBM cannot complete review

    Provide the prior authorization request to the reviewer listed for the drug (ESI, CCUM, or eviCore) or to WPS if the PBM cannot complete the review; reviewer phone numbers are provided in the policy.

    • Include the drug name, HCPCS/J-code, benefit type and clinical justification in the submission.
    • Use vendor phone numbers or WPS contact for submission and escalation.
    Prior Authorization

    Submit PA to designated reviewer or WPS when necessary

    Submit PA to the designated reviewer shown for the drug or to WPS if the PBM reviewer cannot complete the review; WPS accepts submissions for evaluation.

    • Use the reviewer and escalation contact numbers listed in the drug entry.
    • If the group uses an alternate PBM, submit to that PBM per the group's arrangement.
    Prior Authorization

    Use ESI/CCUM/eviCore routing; escalate to WPS if required

    Submit PA to ESI, CCUM, or eviCore according to the reviewer routing shown for each drug; if those reviewers cannot complete the review, submit the PA to WPS for evaluation.

    • Follow the per‑drug reviewer assignment shown in the policy.
    • Escalate to WPS using the provided contact when external reviewers cannot complete review.
    Prior Authorization

    Submit to WPS when vendor cannot complete review; follow alternate PBM guidance

    When external reviewers cannot complete the PA review, submit the prior authorization request to WPS for evaluation; if the group uses another PBM, submit to that PBM as appropriate.

    • WPS contact for escalations: 1-800-333-5003.
    • For groups not using ESI through WPS, use the alternate PBM’s submission process (iExchange or PA form fax).
    Documentation Required

    Submit PA to designated reviewer; include clinical support

    Submit the prior authorization request to the reviewer indicated in the drug entry; if reviewers cannot complete the review, submit to WPS using the WPS contact number provided.

    • Provide drug name and supporting clinical documentation when submitting the PA.
    • Follow the reviewer phone contacts listed in the policy for initial submission.
    Prior Authorization

    Submit PA to WPS if vendor cannot complete review

    If a PBM cannot complete the review, submit the PA request to WPS for evaluation using the contact provided in the policy.

    • WPS contact for evaluation: 1-800-333-5003.
    • If external reviewer cannot complete review, WPS will accept the submission for evaluation.
    Prior Authorization

    Submit to vendor reviewers or escalate to WPS

    Submit PA requests to the listed reviewer (ESI, CCUM, or eviCore) per the reviewer routing; when reviewers cannot complete review, submit to WPS for evaluation and use the phone contacts provided.

    • Use the reviewer phone number 1-800-475-1954 for vendor submissions.
    • Escalate to WPS at 1-800-333-5003 if external vendors cannot complete the review.
    Documentation Required

    Provide drug and clinical info and submit PA to reviewer or WPS

    Submit the prior authorization to the reviewer shown for the drug or to WPS if the PBM cannot complete the review; reviewer phone numbers and WPS contact are provided in the policy.

    • Provide drug name, HCPCS/J-code and supporting clinical information with the PA submission.
    • If the group uses an alternate PBM, submit to that PBM per their process.
    Prior Authorization

    Submit to assigned vendors; escalate to WPS when needed

    Submit PA to ESI, CCUM, or eviCore as listed; if those reviewers cannot complete the review, submit the PA to WPS for evaluation using the contact information supplied.

    • Follow per‑drug reviewer routing; include clinical documentation.
    • Use WPS contact 1-800-333-5003 for escalations when external reviewers cannot complete review.
    Prior Authorization

    Submit PA to listed reviewer or alternate PBM; escalate to WPS if needed

    Submit the prior authorization to the listed reviewer (ESI, CCUM, or eviCore) or to WPS if those reviewers cannot complete the review. If the plan uses a PBM other than ESI through WPS, submit to that PBM.

    • If using another PBM, follow that PBM’s submission process (iExchange or PA form fax options noted in the policy).
    • When vendor reviews cannot be completed, WPS will accept the submission for evaluation.
    Prior Authorization

    Submit PA to listed reviewer; escalate to WPS if reviewer cannot complete

    Submit PA to the vendor listed for the drug; if the external reviewer is unable to complete the review, submit the PA to WPS for evaluation using the WPS contact number.

    • Include HCPCS/J-code and clinical justification in the submission.
    • WPS escalation contact: 1-800-333-5003.
    Documentation Required

    Include drug name and supporting clinical documentation with PA

    Provide the drug name and supporting clinical information (medical records, prior treatments, FDA labeling, literature) when submitting PA to the listed reviewer (ESI, CCUM, eviCore) or to WPS if the PBM cannot complete review.

    • Medical records and prior treatment history should be included.
    • Cite FDA labeling or peer‑reviewed literature when relevant to support medical necessity.
    Denial Risk

    Coverage subject to medical necessity; investigational services not covered

    Coverage is subject to medical necessity; services deemed experimental, investigational, and/or unproven will not be covered.

    • Ensure documentation supports medical necessity and is consistent with evidence‑based guidelines.
    • Requests for experimental or investigational uses may be denied.
    Denial Risk

    Denial risk if PA not obtained

    Failure to obtain prior authorization for any drug on this list may result in denial of coverage.

    • All drugs listed require PA prior to coverage.
    • Claims submitted without an approved PA may be denied or processed as non‑authorized.
    Denial Risk

    Claims may be denied without PA

    All drugs on this list require prior authorization; claims submitted without PA may be denied.

    • PA must be approved by the designated reviewer for coverage to be authorized.
    • If the reviewer cannot complete the review, submit to WPS to avoid denial risk.
    Denial Risk

    Claim denial risk if PA not submitted

    Failure to submit a prior authorization for any drug on the list may result in denial of coverage because all drugs listed require a PA.

    • Submit PA before dispensing or administration to avoid claim denial.
    • When in doubt, submit to the designated reviewer or escalate to WPS.
    Denial Risk

    Requests denied if PA not obtained

    All drugs on this list require PA; requests will be denied if prior authorization is not obtained.

    • Do not administer or dispense listed drugs without PA approval when coverage is sought from WPS.
    • Use vendor or WPS submission routes provided to obtain authorization.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Examples
    Chunks list multiple drugs with Benefit Type = M for medical-administered (e.g., bevacizumab, carboplatin) and P for pharmacy products (e.g., empagliflozin).
    Reviewer options and routing
    Reviewer optionsESI, CCUM, eviCore or WPS are listed as reviewers; use the reviewer specified for each drug entry.
    Phone contactsReviewer phone numbers provided in document (e.g., ESI/CCUM/eviCore : 1-800-475-1954; WPS : 1-800-333-5003).
    Indication-based routingSome drugs route to different reviewers by indication (e.g., CCUM non-oncology, eviCore oncology).
    Reviewer (delegated entity)
    Designated reviewer roleDelegated entity (ESI, CCUM, eviCore) or WPS is responsible for conducting prior authorization reviews as indicated per drug.
    When to escalateIf the designated reviewer cannot complete the review, submit the request to WPS for evaluation.
    Reviewer assignment per drugEach drug entry includes the reviewer assignment and option number (e.g., eviCore (option 3), CCUM (option 2), ESI (option 1)).
    Benefit Type (alternate)
    Benefit TypeIndicates whether the drug is processed under the Pharmacy (P) or Medical (M) benefit for the member as listed per drug.
    Policy implicationBenefit Type affects coding (HCPCS for medical-administered products) and reviewer routing.
    Example entriesChunks include multiple examples where Benefit Type = M for infusion/medical products and P for pharmacy-dispensed drugs.
    Benefit Type (medical/pharmacy indicator)
    Benefit Type indicatorIndicates whether the drug is processed as Pharmacy (P) or Medical (M) benefit as shown in each drug listing.
    Operational noteMedical benefit entries typically include HCPCS codes for facility/infusion billing.
    Reviewer linkBenefit Type entries are paired with reviewer assignments in the source document for routing decisions.
    Reviewer (designated per drug)
    Reviewer (designated)The external utilization management organization (ESI, CCUM or eviCore) or WPS is designated per drug to perform PA reviews.
    EscalationWPS accepts submissions if the PBM/vendor cannot complete the review; submit to WPS using the provided contact number.
    Per-drug assignmentEach drug listing includes the designated reviewer and option number (e.g., CCUM (option 2), ESI (option 1), eviCore (option 3)).
    Benefit Type (alternate chunk)
    Benefit Type indicator (alt)P = Pharmacy or M = Medical as noted per drug; determines billing and reviewer routing.
    Relation to HCPCSMedical benefit (M) entries include HCPCS/Q-codes for administration and facility billing.
    Submission guidanceFollow the Benefit Type shown on the drug entry when preparing the PA request and coding.
    Reviewer — escalation and submission
    Reviewer — operational noteUtilization management entity (ESI, CCUM or eviCore) is responsible for reviewing the PA; if the PBM cannot complete the review, submit to WPS for evaluation.
    Contact infoReviewer phone lines are provided in the source (e.g., 1-800-475-1954 for ESI/CCUM/eviCore; 1-800-333-5003 for WPS).
    Routing by indicationSome oncology agents route to eviCore while non-oncology uses CCUM or ESI as noted per drug entry.